Provided By GlobeNewswire
Last update: May 8, 2025
DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended March 31, 2025, and provided updates on its business.
Read more at globenewswire.comNASDAQ:GHRS (6/4/2025, 8:00:01 PM)
12.43
+0.35 (+2.9%)
Find more stocks in the Stock Screener